VYNE
VYNE·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 1
Bearish signal 3
MACD Golden Cross
EPS Below Expectations
Revenue Below Expectations
Consecutive Revenue Decline
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About VYNE
Vyne Therapeutics Inc.
A clinical stage bio-pharmaceutical company that developing medicines for chronic pruritus and cough
Pharmaceutical
Invalid Date
01/25/2018
NASDAQ Stock Exchange
13
12-31
Common stock
685 Route 202/206 N., Suite 301, Bridgewater, New Jersey 08807
--
VYNE Therapeutics Inc., founded in October 2011, is a Delaware corporation named Tigercat Pharma, Inc. The Company is a clinical-stage biopharmaceutical company focused on the development of proprietary, innovative and differentiated therapies for the treatment of immune inflammatory diseases.
Company Financials
EPS
VYNE has released its 2025 Q2 earnings. EPS was reported at -0.13, versus the expected -0.29, beating expectations. The chart below visualizes how VYNE has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
VYNE has released its 2025 Q3 earnings report, with revenue of 169.00K, reflecting a YoY change of 39.67%, and net profit of -7.28M, showing a YoY change of 40.12%. The Sankey diagram below clearly presents VYNE's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
